Efficacy of etanercept for treating the active rheumatoid arthritis: an updated meta-analysis

Abstract

Aim: To evaluate the efficacy of etanercept (ETA) for treating active rheumatoid arthritis (RA) compared to placebo or methotrexate (MTX). Methods: We searched Medline, Cochrane Library and Wiley databases. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare efficacy. Results: In total, 12 studies with 3878 active RA patients (including 2046 patients treated with ETA and 1832 patients treated with placebo or MTX) were included. The overall RRs in ACR20, 50 and 70 (20%, 50%, 70% improvement based on the criteria of American Rheumatism Association) were 2.10 (95% CI: 1.45–3.02, P < 0.0001), 2.87 (95% CI: 1.66–4.97, P = 0.0002) and 2.16 (95% CI: 1.49–3.13, P < 0.0001) within 24 weeks, respectively and were 1.19 (95% CI: 1.11–1.28, P < 0.00001), 1.37 (95% CI: 1.22–1.53, P < 0.00001) and 1.57 (95% CI: 1.28–1.92, P < 0.00001) within 1–3 years, respectively. Further, the overall RRs of 25 mg versus 10 mg ETA twice weekly in ACR20, 50 and 70 were 1.10 (95% CI: 1.02–1.19, P < 0.02), 1.37 (95% CI: 0.98–1.92, P < 0.07) and 1.27 (95% CI: 1.02–1.58, P < 0.03), respectively. Conclusions: In active RA patients treated with ETA, there was significantly higher efficacy compared to the treatment of placebo or MTX. High doses of ETA were more effective for active RA patients.